Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer

July 21, 2015

Join Jaffer Ajani, MD and Brian Badgwell, MD as they present their multidisciplinary expertise on a range of cases pertaining to gastric cancer.

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Surgery with lymph node dissection is the primary treatment for patients with localized resectable gastric cancer. However, surgery alone is an insufficient therapy for most patients due to high rate of recurrences and poor overall survival rates. Combined modality therapy should be considered for all patients with localized gastric cancer treated with a curative intent. The results of several randomized trials support the use of preoperative and/or postoperative therapy (perioperative chemotherapy, postoperative chemoradiation or postoperative chemotherapy) as an adjunct to surgery. The choice of appropriate preoperative and/or postoperative therapy depends on the stage of the disease, the type of lymph node dissection (D1 vs. D2) and surgical margins (R0 vs. R1/R2 resections). Current research is focused on understanding the molecular heterogeneity of gastric cancer and developing more effective targeted therapies for advanced or metastatic disease.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Develop an individualized treatment plan for patients with localized gastric cancer as outlined in the clinical practice guidelines
  • Identify patients with advanced or metastatic gastric or EGJ adenocarcinoma most likely to benefit from the newly approved targeted therapies
Additional information

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
Course expires: 
Event starts: 
07/21/2015 - 3:30pm EDT
Event ends: 
07/21/2015 - 4:30pm EDT

Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center

Brian Badgwell, MD
The University of Texas MD Anderson Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing